Complement inhibitor membrane cofactor protein (MCP; CD46) is constitutively shed from cancer cell membranes in vesicles and converted by a metalloproteinase to a functionally active soluble form

被引:74
作者
Hakulinen, J
Junnikkala, S
Sorsa, T
Meri, S
机构
[1] Univ Helsinki, Biomedicum A506B, Dept Bacteriol & Immunol, Haartman Inst, FIN-00290 Helsinki, Finland
[2] Univ Helsinki, Cent Hosp, Inst Dent, Dept Oral & Maxillofacial Dis, Helsinki, Finland
关键词
cell surface molecules; complement; inflammation; tumor immunity;
D O I
10.1002/eji.200424969
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Human cell-surface protein CD46 protects cells from complement damage, regulates immune functions through signaling and acts as a receptor for certain pathogenic microbes. Multiple molecular weight isoforms of membrane bound CD46 are produced by alternative splicing of the CD46 mRNA in an area coding for the serine/threonine/proline-rich region or for the cytoplasmic tail. We demonstrate that CD46 becomes proteolytically modified on cell membranes. We observed that tumor cells liberated intact 60-65 kDa forms of CD46 into the cell culture medium on the surface of vesicles with a diameter of 200 nm. Furthermore, soluble CD46 (55-60 kDa) containing the glycosylated STP-region but lacking the hydrophobic transmembrane sequence and cytoplasmic domains was released from tumor cell membranes. The use of selective inhibitors indicated that CD46 release is due to specific cleavage by a metalloproteinase. Exposure of the cells to hydrogen peroxide (H2O2) or their detachment from the pericellular matrix increased the shedding of soluble CD46. Both vesicular and soluble forms of CD46 remained functional and promoted C3b cleavage by factor I. The results show that the functional activity of CD46 is not restricted to the tumor cell membranes but can be liberated in vesicles and by a metalloproteinase.
引用
收藏
页码:2620 / 2629
页数:10
相关论文
共 32 条
[21]   Linking innate and acquired immunity: divergent role of CD46 cytoplasmic domains in T cell-induced inflammation [J].
Marie, JC ;
Astier, AL ;
Rivailler, P ;
Rabourdin-Combe, C ;
Wild, TF ;
Horvat, B .
NATURE IMMUNOLOGY, 2002, 3 (07) :659-666
[22]   THERAPEUTIC REGULATION OF THE COMPLEMENT-SYSTEM IN ACUTE INJURY STATES [J].
MOORE, FD .
ADVANCES IN IMMUNOLOGY, VOLUME 56, 1994, 56 :267-299
[23]   MEMBRANE COFACTOR PROTEIN OF THE COMPLEMENT-SYSTEM - ALTERNATIVE SPLICING OF SERINE THREONINE PROLINE RICH EXONS AND CYTOPLASMIC TAILS PRODUCES MULTIPLE ISOFORMS THAT CORRELATE WITH PROTEIN PHENOTYPE [J].
POST, TW ;
LISZEWSKI, MK ;
ADAMS, EM ;
TEDJA, I ;
MILLER, EA ;
ATKINSON, JP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (01) :93-102
[24]  
SBARBA PD, 2002, BIOL CHEM, V383, P69
[25]   PURIFICATION AND FUNCTIONAL-PROPERTIES OF SOLUBLE FORMS OF MEMBRANE COFACTOR PROTEIN (CD46) OF COMPLEMENT - IDENTIFICATION OF FORMS INCREASED IN CANCER-PATIENTS SERA [J].
SEYA, T ;
HARA, T ;
IWATA, K ;
KURIYAMA, S ;
HASEGAWA, T ;
NAGASE, Y ;
MIYAGAWA, S ;
MATSUMOTO, M ;
HATANAKA, M ;
ATKINSON, JP ;
NAGASAWA, S .
INTERNATIONAL IMMUNOLOGY, 1995, 7 (05) :727-736
[26]   Tetracycline inhibits Porphyromonas gingivalis lipopolysaccharide-induced lesions in vivo and TNF alpha processing in vitro [J].
Shapira, L ;
Houri, Y ;
Barak, V ;
Soskolne, WA ;
Halabi, A ;
Stabholz, A .
JOURNAL OF PERIODONTAL RESEARCH, 1997, 32 (01) :183-188
[27]   Urine levels of CD46 (membrane cofactor protein) are increased in patients with glomerular diseases [J].
Shoji, T ;
Nakanishi, I ;
Kunitou, K ;
Tsubakihara, Y ;
Hirooka, Y ;
Kishi, Y ;
Hatanaka, M ;
Matsumoto, M ;
Toyoshima, K ;
Seya, T .
CLINICAL IMMUNOLOGY, 2000, 95 (02) :163-169
[28]   Elevated serum and cerebrospinal fluid levels of soluble human herpesvirus type 6 cellular receptor, membrane cofactor protein, in patients with multiple sclerosis [J].
Soldan, SS ;
Fogdell-Hahn, A ;
Brennan, MB ;
Mittleman, BB ;
Ballerini, C ;
Massacesi, L ;
Seya, T ;
McFarland, HF ;
Jacobson, S .
ANNALS OF NEUROLOGY, 2001, 50 (04) :486-493
[29]   Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells [J].
Taraboletti, G ;
D'Ascenzo, S ;
Borsotti, P ;
Giavazzi, R ;
Pavan, A ;
Dolo, V .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 160 (02) :673-680
[30]   MMP inhibition and downregulation by bisphosphonates [J].
Teronen, O ;
Heikkilä, P ;
Konttinen, YT ;
Laitinen, M ;
Salo, T ;
Hanemaaijer, R ;
Teronen, A ;
Maisi, P ;
Sorsa, T .
INHIBITION OF MATRIX METALLOPROTEINASES: THERAPEUTIC APPLICATIONS, 1999, 878 :453-465